CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

EACS 2021

18th European AIDS Conference

October 27 - 30, 2021
Virtual

  • Cabotegravir

    Hocqueloux L, et al.

    Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB+RPV LA): Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL). Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    de los Rios P, et al.

    Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Elliot E, et al.

    Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. Best Poster Presentation.

    View Poster

    Gutner C, et al.

    Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): Examining Health Care Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir + Rilpivirine Long-Acting Injectable (CAB+RPV LA) for People Living With HIV (PLHIV). Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Gutner C, et al.

    Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment: Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL). Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Molina JM, et al.

    European Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Snedecor SJ, et al.

    Indirect Comparison of 96-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months Versus Dolutegravir/Abacavir/Lamivudine in Suppressed HIV-1 Infected Participants. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Teichner P, et al.

    Outcomes for Participants During Long-term Follow-up After Discontinuation of Cabotegravir + Rilpivirine Long-Acting in the Phase III/IIIb Clinical Trials. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. Oral Presentation.

    View Poster

  • Dolutegravir

    Fernvik E, et al.

    Impact of Treatment Adherence on Efficacy of DTG + 3TC and DTG + TDF/FTC: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Taylor S, et al.

    Switching to DTG/3TC Is Non-inferior to Continuing Current Antiretroviral Regimen at Week 48: SALSA Subgroup Analyses. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Scholten S, et al.

    Switching to DTG/3TC Is Non-inferior to Continuing a TAF-Based Regimen at Week 144: TANGO Subgroup Analyses. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Wang R, et al.

    Evaluating the Relationship Between Inflammation Biomarker Interleukin-6 (IL-6) Levels and Residual, Low-Level Viraemia in HIV-1 Suppressed Participants in the TANGO Study at Week 96 (WK96). Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Ummard-Berger K, et al.

    2 year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: Real-world data from the German JUNGLE cohort. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Mussini C, et al.

    Highly Effective Two-drug Regimens of an Integrase Inhibitor and Reverse Transcriptase Inhibitor in Real-World Setting - Data from COMBINE-2 Study. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Byonanebye DM, et al.

    Incidence of hypertension in PLWH receiving InSTI versus other third drug ART regimens in the RESPOND cohort. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Spinelli F, et al.

    Durable Efficacy and Safety of DTG + 3TC in Treatment-Naive People With HIV-1 Stratified by Age: 144-Week Results From GEMINI-1 and -2. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

  • Fostemsavir

    Jacob I, et al.

    Comparative Efficacy of Fostemsavir Versus Ibalizumab in Heavily Treatment-Experienced HIV Patients. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Clark A, et al.

    Long-term Inflammation Biomarker Changes With Fostemsavir in Heavily Treatment-Experienced Adults With HIV-1: Exploratory Analyses of the Phase 3 BRIGHTE Study. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

    Gartland M, et al.

    Emergent Resistance to Antiretroviral (ARV) Agents Used in Optimized Background Therapy (OBT) With Fostemsavir (FTR): Week 96 Results of the Phase 3 BRIGHTE Study in Heavily Treatment-Experienced (HTE) Adults Living With Multidrug-Resistant (MDR) HIV-1. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. Best Poster Presentation.

    View Poster

  • Disease State

    Dakhia S, et al.

    Understanding the Perceived Therapeutic Need and Value Associated With Novel Long-Acting Antiretroviral Regimens Among People Living With HIV in 12 European Countries. Presented at the 18th European AIDS Conference (EACS), October 27-30, 2021, Online & London, United Kingdom. ePoster Presentation.

    View Poster

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

My MSL

Enter zip code to find your MSL contact.